Compare PIPR & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIPR | COGT |
|---|---|---|
| Founded | 1895 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.5B |
| IPO Year | N/A | 2018 |
| Metric | PIPR | COGT |
|---|---|---|
| Price | $377.84 | $39.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $362.50 | $32.08 |
| AVG Volume (30 Days) | 105.5K | ★ 2.2M |
| Earning Date | 02-06-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | ★ 42.49 | N/A |
| EPS | ★ 13.30 | N/A |
| Revenue | ★ $1,717,433,000.00 | N/A |
| Revenue This Year | $17.96 | N/A |
| Revenue Next Year | $14.78 | N/A |
| P/E Ratio | $28.08 | ★ N/A |
| Revenue Growth | ★ 13.46 | N/A |
| 52 Week Low | $202.91 | $3.72 |
| 52 Week High | $380.00 | $43.73 |
| Indicator | PIPR | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 63.07 | 61.99 |
| Support Level | $364.94 | $37.70 |
| Resistance Level | $379.54 | $40.40 |
| Average True Range (ATR) | 9.87 | 1.90 |
| MACD | 1.04 | 0.31 |
| Stochastic Oscillator | 92.65 | 83.19 |
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.